Our group has also recently measured, by flow cytometry, the CD34+/CD26+ LSCs in bone marrow and peripheral blood from CML patients at diagnosis, during treatment with TKIs and in TFR, confirming that CD26 is a CML-specific marker (15). Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.